Pectolvan C syrup 100 ml — Made in Ukraine — Free Delivery

Pharmacological properties

Pharmacodynamics. Pectolvan C is a combined mucolytic and expectorant agent containing a balanced combination of two medical ingredients - ambroxol and carbocisteine.

Ambroxol is an active metabolite of bromhexine, but more effective. Increases the secretion of the glands of the respiratory tract, promotes the dilution of viscous bronchial secretions and facilitates its discharge by increasing mucociliary clearance, changes the ratio of serous and mucous components of sputum. Stimulates Clara cells and activates hydrolyzing enzymes, which also leads to a decrease in the viscosity of sputum. Ambroxol has secretomotor properties, stimulates the ciliated epithelium of the bronchi, restores the drainage function of small bronchi and bronchioles. The preparation stimulates the formation of endogenous surfactant, does not cause excessive secretion, reduces spastic hyperreactivity of the bronchi. Cough and sputum volume are significantly reduced. Ambroxol hydrochloride has shown anti-inflammatory effects in vitro. In vitro studies have shown that ambroxol hydrochloride significantly reduces the release of cytokines from the blood and tissue binding of mononuclear and polymorphonuclear cells.

Carbocisteine ​​exhibits mucolytic and expectorant effects by breaking the disulfide bridges of glycoproteins, causing the overly viscous secretion of the bronchi to liquefy, which promotes the excretion of phlegm. The mucoregulatory effect of carbocisteine ​​is associated with the activation of sialic transferase, an enzyme of the goblet cells of the bronchial mucosa. Normalizes the quantitative ratio of acidic and neutral sialomucins, which helps to reduce the viscosity of bronchial secretions. Facilitates sputum discharge by increasing mucociliary clearance, has antioxidant and pneumoprotective properties due to the ability of sulfhydryl groups to bind free radicals. It also promotes the regeneration of the mucous membrane, normalizes its structure and reduces the hyperplasia of the goblet cells and, as a result, reduces the production of mucus. It activates the activity of the ciliated epithelium, restores the secretion of IgA (specific protection) and the number of sulfhydryl groups of mucus components (non-specific protection). Shows an anti-inflammatory effect due to the kinin-inhibiting activity of sialomucins, which leads to a decrease in edema and bronchial obstruction.

Pharmacokinetics. After taking ambroxol, it is almost completely absorbed in the digestive tract, it penetrates well into the lung tissue. Absolute oral bioavailability is 70-80%. Cmax in blood plasma is reached approximately 2 hours after oral administration. T½ - 7-12 hours. It is excreted mainly in the urine (up to 90%). Penetrates through the BBB, into breast milk, does not accumulate.

When taken orally, carbocisteine ​​is rapidly absorbed. Cmax of the active substance in blood plasma is achieved after 2 hours. Bioavailability is low - less than 10% of the administered dose (due to intensive metabolism in the gastrointestinal tract and the effect of the first passage through the liver). Carbocisteine ​​is excreted almost completely in the form of inactive metabolites (inorganic sulfates, diacetylcysteine) in the urine. Only a small amount is excreted unchanged in the feces. It can penetrate the placental barrier and accumulate in the amniotic fluid.

Indications

Acute and chronic diseases of the respiratory tract, accompanied by the formation of difficult sputum:

• COPD;
• pneumonia;
• BA with difficult sputum;
• bronchiectasis;
• respiratory distress syndrome;
• treatment for complications after surgery on the lungs;
• when caring for a tracheostomy, before and after bronchoscopy;
• inflammatory diseases of the middle ear and paranasal sinuses.

Application

Apply internally.

Adults and children over the age of 12 years - 10 ml (2 dosing spoons) 3 times a day.

Children aged 6-12 years - 5 ml (1 dosing spoon) 2-3 times a day, at the age of 2-6 years - 2.5 ml (½ dosing spoon) 2-3 times a day.

The duration of treatment, as a rule, should not exceed 7-10 days.

The duration of use in children should be as short as possible, no more than 5 days.

Contraindications

Hypersensitivity to the components of the preparation. in the case of rare hereditary conditions, in connection with which incompatibility with the excipients of the preparation is possible (see special instructions), the use of the preparation is contraindicated.

Peptic ulcer of the stomach and duodenum during an exacerbation. I trimester of pregnancy due to insufficient data on teratogenic and embryotoxic effects.

Side effects

From the immune system: hypersensitivity reactions, including angioedema, anaphylactic reactions, anaphylactic shock;

on the part of the skin and subcutaneous tissue: skin rash (pinpoint, spotty, small-spotted, draining plaques), urticaria, itching, dermatitis, severe skin lesions, including Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome);

from the nervous system: dysgeusia (taste disturbances), dizziness, headache, anxiety;

from the digestive tract: nausea, decreased sensitivity in the mouth, vomiting, diarrhea, dyspepsia, heartburn, stomach pain, abdominal pain, indigestion, dry mouth, constipation, salivation, dry throat, gastrointestinal bleeding;

from the respiratory system, chest and mediastinal organs: decreased sensitivity in the pharynx, rhinorrhea, dyspnea (as a symptom of a hypersensitivity reaction).

from the urinary system: dysuria;

from the heart: a feeling of palpitations;

general disorders: general weakness, fever, reactions from the mucous membrane.

Special instructions

A productive cough is a fundamental defense mechanism of the bronchopulmonary system and as such should not be suppressed. the combination of preparations that modify bronchial secretion with preparations that suppress cough and / or substances that reduce secretion (atropine group) is irrational.

The use of mucolytic agents can lead to impaired bronchial patency in infants. In children under 1 year of age, the ability to clear the airways from bronchial secretions is limited due to age-related anatomical and physiological characteristics. Any mucolytic agents should not be used in infants.

It is necessary to reconsider the treatment if there is no effect or an increase in the symptoms of the disease.

There is evidence of severe skin lesions: Stevens-Johnson syndrome and Lyell's syndrome, coinciding in time with the use of ambroxol. Basically, they could be explained by the severity of the underlying disease and / or the simultaneous use of another preparation. Therefore, if new lesions of the skin or mucous membranes appear, you should immediately seek medical attention and stop treatment with Ambroxol hydrochloride.

In case of impaired bronchial motility and increased mucus secretion (for example, in such a rare disease as primary ciliary dyskinesia), the preparation should be used with caution, since Ambroxol can increase mucus secretion.

Patients with impaired renal function or severe hepatic impairment should take the preparation only after consulting a doctor. When using ambroxol, like any active substance that is metabolized in the liver, and then excreted by the kidneys, there is an accumulation of metabolites formed in the liver in patients with severe renal failure.

It is necessary to carry out careful medical supervision in the discharge of purulent sputum, high body temperature.

The preparation should be used with caution when treating patients with a history of gastric or duodenal ulcers.

The preparation contains sorbitol, so patients with rare hereditary fructose intolerance should not take it.

The preparation contains aspartame, which is a phenylalanine derivative, which can be dangerous for people with phenylketonuria.

The preparation contains glucose, therefore, patients with hereditary glucose intolerance, glucose-galactose malabsorption should avoid taking it.

Use during pregnancy and lactation. The use of the preparation is contraindicated in the first trimester of pregnancy. In the II and III trimester of pregnancy, the preparation is used only after a careful assessment of the ratio of benefit to the mother / risk to the fetus (child), which is determined by the doctor. Not recommended for use during breastfeeding.

Children. The preparation can be used in children from the age of 2 years. Children should be treated under medical supervision.

The ability to influence the reaction rate when driving or working with other mechanisms. Studies of the effect on the reaction rate when driving vehicles or working with other mechanisms have not been conducted. If dizziness occurs, you should refrain from driving or working with other mechanisms.

Interactions

Increases the effectiveness of glucocorticoid and antibacterial therapy in the treatment of inflammatory diseases of the upper and lower respiratory tract. however, it is not recommended to use it simultaneously with tetracycline antibiotics (with the exception of doxycycline), the interval between their use should be at least 2 hours.

The simultaneous use of ambroxol and cough suppressants can lead to excessive accumulation of mucus due to inhibition of the cough reflex. Therefore, such a combination is possible only after a thorough assessment by the physician of the ratio of the expected benefit and the possible risk during use.

During the period of treatment with carbocisteine, antitussives and preparations that suppress bronchial secretion should not be used.

Overdose

Symptoms: stomach pain, nausea, vomiting, diarrhea.

Treatment: symptomatic and supportive.

Storage conditions

Store in its original packaging at a temperature not exceeding 25 ° C. do not refrigerate.

The shelf life after opening the bottle is 60 days at a temperature not higher than 25 ° C. Do not refrigerate.

Keep out of the reach of children.